Perspectives on Universal Healthcare Coverage

The innovative biopharmaceutical industry believes that a structured, collaborative effort to achieve universal health coverage can meet the shared goals of global health stakeholders of expanding patient access to quality medicines through innovative solutions and long-term sustainability of the health sector.

Novartis partners with Malaria No More to provide treatment in Zambia

Novartis announced on Monday that it will partner with Malaria No More and the Power of One campaign to provide two million pediatric antimalarial treatments in Zambia.

“Although the incidence of malaria has decreased, the disease still kills a child every minute in Africa,” Novartis CEO Joseph Jimenez said. “Our commitment to Power of One reflects our company’s long-term efforts to fight malaria and Novartis remains dedicated to controlling and ultimately eliminating this deadly disease.”

Innovation and Access – ways to sustain and improve Health Outcomes

Online Q&A with Eli Lilly’s John Lechleiter
April 2, 2014.  9:00am - 10:00am, EDT

Global Health Progress and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) are proud to host an hour-long, conversation focused on the promise of medical innovation for global health with John C. Lechleiter - Chairman, President and CEO of Eli Lilly and President of IFPMA.

Uniting to Combat Neglected Tropical Diseases: A Conversation on Progress

On April 2, the Uniting to Combat Neglected Tropical Diseases: A Conversation on Progress webcast and live Q&A will be broadcast from Institut Pasteur in Paris from 18:00 - 19:30 Central European Summer Time/12:00 - 13:30 Eastern Daylight Time. Panelists will address progress and challenges in the effort to control and eliminate 10 NTDs by 2020, with an overarching theme of how the unique alliance of pharmaceutical companies, development agencies, endemic countries, research organizations and private foundations has driven progress forward since the launch of the London Declaration on Neglected Tropical Diseases in 2012.

WHO South-East Asia Region certified polio-free

WHO South-East Asia Region, home to a quarter of the world’s population, was certified polio-free today by an independent commission under the WHO certification process. This is the fourth of six WHO Regions to be certified, marking an important step towards global polio eradication. With this step, 80% of the world’s population now lives in certified polio-free regions.

Pharmaceutical R&D Projects to Develop New Cures for Patients with Neglected Conditions

The research-based pharmaceutical industry is actively involved in the fight against diseases affecting vulnerable populations. With 162 compounds in development, R&D programs and pipelines show industry’s commitment to these pressing health challenges. Most of these R&D projects are carried out through innovative collaborations with non-industry partners.

Eliminating or controlling neglected diseases is achievable. Success relies on multi-stakeholder approaches, which not only drive further R&D but also integrate environmental improvements, boosting capacity-building efforts, effective health policies, better screening, and availability of high quality, safe and effective medicines.

Rethinking Pharmaceutical Business Models

The world’s health needs are changing dramatically. Demographic trends, shifting patterns of disease, and strained public funding are placing new burdens on health-care systems. For developed and developing countries alike, the new demands cannot be met if health care continues to operate in the same way. What is required are new business models that spread risks, take a broader view of health, and address the needs of the world’s poorest people.

India to Strengthen R&D of New Diagnostics, Vaccines & Treatments for Neglected Tropical Diseases

Leading the global fight against Neglected Tropical Diseases (NTDs), India is moving to strengthen efforts to eradicate the neglected tropical diseases such as dengue, visceral leishmaniasis (Kala azar), soil-transmitted Helminths, among others that affect millions of Indians every year especially children. There is urgent need to accelerate research and development for new tools, medicines and indigenous tests that target pathogen strains that are locally prevalent and adopt and accelerate strategies to reach the poorest and most marginalized populations who are most afflicted by NTDs.

Addressing neglected tropical diseases: research, development and access to treatments

According to the WHO, Neglected Tropical Diseases (NTDs) affect over 1 billion people worldwide, and are devastating to patients in the developing world. These diseases kill or disable millions of people every year. These diseases were highlighted in a recent PhRMA Conversation in which PhRMA President and CEO John J. Castellani asked a variety of experts for their opinion on "What is being done to get treatments to these patients and to speed development of new treatments?" The 2013 G-FINDER report was also recently released, addressing global funding of innovation for neglected diseases.

Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa. Through this program, Janssen will donate its HIV medicines PREZISTA® (darunavir) and INTELENCE® (etravirine), including child-friendly formulations, free of charge to eligible countries with the clinical capacity and willingness to address second- and third-line pediatric HIV treatment. Each child enrolled will receive Janssen's donated HIV medicines as needed until they turn 19 at which point they will be transitioned into the adult national HIV program or other designated by the national HIV program for continued treatment.